INTRODUCTION: Circulating endothelial cells (CECs) increase in cancer patients and play an important role in tumor neovascularization. METHODS: This study was designed to investigate the role of CEC as a marker for predicting the effectiveness of a carboplatin plus paclitaxel based first line chemotherapy in advanced non-small cell lung cancer (NSCLC). RESULTS: The CEC count in 4 ml of peripheral blood before starting chemotherapy (baseline value) was significantly higher in NSCLC patients, ranging from 32 to 4501/4 ml (n = 31, mean +/- SD = 595 +/- 832), than in healthy volunteers (n = 53, 46.2 +/- 86.3). We did not detect a significant correlation between the CEC count and estimated tumor volume. CECs were significantly decreased by chemotherapy as compared with pretreatment values (175.6 +/- 24 and 173.0 +/- 24, day +8, +22, respectively). We investigated the correlation between baseline CEC and the clinical effectiveness of chemotherapy. CEC values are significantly higher in patients with clinical benefit (partial response and stable disease, 516 +/- 458, 870.8 +/- 1215, respectively) than in progressive disease patients (211 +/- 150). Furthermore, a statistically significant decrease in CECs, on day 22, was observed only in patients with partial response. Patients who had a baseline CEC count greater than 400/4 ml showed a longer progression-free survival (>400, 271 days [range: 181-361] versus <400, 34 [range: 81-186], p = 0.019). CONCLUSION: CEC is suggested to be a promising predictive marker of the clinical efficacy of the CBDCA plus paclitaxel regimen in patients with NSCLC.
INTRODUCTION: Circulating endothelial cells (CECs) increase in cancerpatients and play an important role in tumor neovascularization. METHODS: This study was designed to investigate the role of CEC as a marker for predicting the effectiveness of a carboplatin plus paclitaxel based first line chemotherapy in advanced non-small cell lung cancer (NSCLC). RESULTS: The CEC count in 4 ml of peripheral blood before starting chemotherapy (baseline value) was significantly higher in NSCLCpatients, ranging from 32 to 4501/4 ml (n = 31, mean +/- SD = 595 +/- 832), than in healthy volunteers (n = 53, 46.2 +/- 86.3). We did not detect a significant correlation between the CEC count and estimated tumor volume. CECs were significantly decreased by chemotherapy as compared with pretreatment values (175.6 +/- 24 and 173.0 +/- 24, day +8, +22, respectively). We investigated the correlation between baseline CEC and the clinical effectiveness of chemotherapy. CEC values are significantly higher in patients with clinical benefit (partial response and stable disease, 516 +/- 458, 870.8 +/- 1215, respectively) than in progressive diseasepatients (211 +/- 150). Furthermore, a statistically significant decrease in CECs, on day 22, was observed only in patients with partial response. Patients who had a baseline CEC count greater than 400/4 ml showed a longer progression-free survival (>400, 271 days [range: 181-361] versus <400, 34 [range: 81-186], p = 0.019). CONCLUSION: CEC is suggested to be a promising predictive marker of the clinical efficacy of the CBDCA plus paclitaxel regimen in patients with NSCLC.
Authors: María Angeles Vaz Salgado; Julie Earl; Victor Rodriguez Berrocal; Freddy Salge Arrieta; Ana Gomez; Juan Manuel Sepulveda-Sanchez; Ángel Perez-Nuñez; Elena Corral de la Fuente; Daniel Lourido; María Villamayor; Hector Pian; Alfonso Muriel; Elisabetta Rossi; Rita Zamarchi; Alfredo Carrato; Luis Ley Journal: Future Sci OA Date: 2022-05-24
Authors: Daniel D Karp; Michael N Pollak; Roger B Cohen; Peter D Eisenberg; Paul Haluska; Donghua Yin; Allan Lipton; Laurence Demers; Kim Leitzel; Mary L Hixon; Leon W Terstappen; Linda Garland; Luis G Paz-Ares; Felipe Cardenal; Corey J Langer; Antonio Gualberto Journal: J Thorac Oncol Date: 2009-11 Impact factor: 15.609